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Background: Preclinical studies have shown that gene therapy is a feasible approach to treat mitochondrial
neurogastrointestinal encephalomyopathy (MNGIE). However, the genetic murine model of the disease
(Tymp/Upp1 double knockout, dKO) has a limited functional phenotype beyond the metabolic imbalances,
and so the studies showing efficacy of gene therapy have relied almost exclusively on demonstrating correc-
tion of the biochemical phenotype. Chronic oral administration of thymidine (dThd) and deoxyuridine
(dUrd) to dKO mice deteriorates the phenotype of the animals, providing a better model to test therapy
approaches.
Methods: dKO mice were treated with both dThd and dUrd in drinking water from weaning until the end of
the study. At 8 - 11 weeks of age, mice were treated with several doses of adeno-associated virus (AAV)
serotype 8 vector carrying the human TYMP coding sequence under the control of different liver-specific pro-
moters (TBG, AAT, or HLP). The biochemical profile and functional phenotype were studied over the life of the
animals.
Findings: Nucleoside exposure resulted in 30-fold higher plasma nucleoside levels in dKO mice compared
with non-exposed wild type mice. AAV-treatment provided elevated TP activity in liver and lowered sys-
temic nucleoside levels in exposed dKO mice. Exposed dKO mice had enlarged brain ventricles (assessed by
magnetic resonance imaging) and motor impairment (rotarod test); both were prevented by AAV treatment.
Among all promoters tested, AAT showed the best efficacy.
Interpretation: Our results show that AAV-mediated gene therapy restores the biochemical homeostasis in
the murine model of MNGIE and, for the first time, demonstrate that this treatment improves the functional
phenotype.
Funding: This work was funded in part by the Spanish Instituto de Salud Carlos III, and the Generalitat de Cat-
alunya. The disclosed funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.







V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE) is caused by mutations in the nuclear gene TYMP [1], which
lead to a deficiency of thymidine phosphorylase (TP) activity andsystemic accumulation of its substrates, the nucleosides thymidine
(dThd) and deoxyuridine (dUrd) [2,3]. dThd and dUrd accumulation
causes an imbalance in the mitochondrial deoxyribonucleoside tri-
phosphate (dNTP) pool that interferes with mitochondrial DNA
(mtDNA) replication, thereby inducing mtDNA depletion, multiple
deletions, and point mutations [4-8].
The main clinical features of MNGIE are progressive gastrointesti-
nal dysmotility, cachexia, ptosis, ophthalmoplegia or ophthalmopare-
sis, demyelinating peripheral neuropathy, symmetrical distal
Research in context
Evidence before this study
Mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE) is a fatal metabolic disease caused by mutations in the
nuclear gene TYMP that encodes thymidine phosphorylase. In
patients, thymidine phosphorylase dysfunction causes accumu-
lation of the nucleosides thymidine and deoxyuridine, which
interferes with mitochondrial DNA replication. Hence, all ther-
apy approaches for MNGIE are addressed to reach permanent
reduction of these toxic metabolites. Over the last years, several
preclinical studies have demonstrated that gene therapy is a
feasible strategy for this disorder. Transduction of hematopoi-
etic progenitors with the correct version of the gene using lenti-
viral vectors, or the liver, using an adeno-associated virus (AAV)
vector, resulted in effective and sustained restoration of nucleo-
side homeostasis in the Tymp/Upp1 double knock out murine
model of this disorder. However, this animal model does not
recapitulate the clinical manifestations of the disease, and all
evidence so far collected supporting gene therapy for MNGIE
relies almost exclusively on demonstrating correction of the
biochemical phenotype in mice.
Added value of this study
Previous studies demonstrated that challenging the MNGIE
mouse model with a chronic oral administration of the toxic
nucleosides exacerbated the model leading to the manifesta-
tion of neurological phenotype and thus providing a better tool
to test therapeutic intervention. In this study, we show that
AAV-mediated gene therapy prevents the enlargement of brain
ventricles and the neuromotor dysfunction observed in the
mice. Hence, we prove that liver-targeted gene therapy using
an AAV vector prevents the manifestation of a neurological
phenotype beyond correcting the biochemical nucleoside
imbalance. This is the first time liver-targeted AAV-mediated
gene therapy for MNGIE shows efficacy on clinical parameters
in the animal model of the disease, which constitutes an impor-
tant step towards the translation of this therapy to patients.
Implications of all the available evidence
At present, hematopoietic stem cell transplantation and liver
transplantation are the only available therapies for MNGIE
patients. However, both treatments are constrained by the
availability of a suitable donor and involve complex medical
interventions associated to life-threatening risks. Gene therapy
may constitute a safer alternative, and this study provides evi-
dence that liver targeted AAV-mediated gene therapy is effec-
tive on the neurological phenotype in the enhanced animal
model of the disease. This will support conducting clinical stud-
ies that will bring this potential treatment closer to patients.
2 F. Vila-Julia et al. / EBioMedicine 62 (2020) 103133weakness, and diffuse leukoencephalopathy on brain magnetic reso-
nance imaging (MRI). Disease onset is usually between the first and
fifth decades, in most cases before the age of 20 years, and the condi-
tion progressively degenerates, causing premature death of affected
patients usually during the third to fourth decade of life [9].
Several therapeutic strategies have been proposed for MNGIE, all
of them addressed to reducing the toxic nucleoside accumulation
[10]. Allogeneic hematopoietic stem cell transplantation was the first
treatment providing a permanent nucleoside reduction and clinical
improvement or stabilization in patients [11,12]. However, it is an
aggressive therapy associated with a high mortality risk due totransplant-related complications, which are aggravated in MNGIE
patients by the poor clinical condition when most are treated [13].
More recently, orthotopic liver transplantation was proposed as an
alternative option [14], and the reported cases indicate that success-
ful engraftment results in a sustained nucleoside reduction [15-18].
However, liver transplantation is also an aggressive intervention, and
it is constrained by a limited supply of donors.
Over the last few years, several preclinical studies have proven the
effectiveness of lentiviral hematopoietic stem cell gene therapy or
liver-targeted adeno-associated virus (AAV) vector gene therapy to
correct MNGIE biochemical disarrangements in a Tymp/Upp1 double
knockout (dKO) mouse model of the disease [5,19-24]. However, as
the dKO mouse model has a limited and elusive functional phenotype
except for its clear metabolic imbalances, these preclinical studies
have relied almost exclusively on demonstrating correction of the
biochemical imbalances caused by the lack of TP activity. It has been
shown that chronic oral administration of dThd and dUrd to dKO
mice significantly enhances the phenotype beyond biochemical
derangements and provides a better model to test therapy
approaches [25]. Taking advantage of this improved model, we show
here that the liver-targeted AAV gene therapy not only corrects the
biochemical imbalances of the nucleoside-stressed model, but also
prevents other functional changes such as those related to its neuro-
logical phenotype.
2. Methods
2.1. Vector construction, production, and titration
The human coding sequence of TYMP (hcTYMP) was cloned in
three different vectors (AAV-TBG, AAV-AAT, and AAV-HLP) and pack-
aged in AAV8 serotype as previously described [19]. AAV-TBG con-
tained hcTYMP under regulation of the thyroxine binding globulin
(TBG) promoter in a single-stranded configuration. AAV-AAT con-
tained hcTYMP under regulation of the a1-antitrypsin promoter
and the apolipoprotein E hepatic control region (ApoE-AAT cassette)
in a single-stranded configuration. AAV-HLP contained hcTYMP
under regulation of the hybrid liver-specific promoter, which is com-
posed of an abbreviated form of the ApoE-AAT cassette [26] in a self-
complementary configuration. For construction of AAV-HLP, the
pAV-HLP-Luc plasmid was provided by Dr. Nathwani’s group (Uni-
versity College London Cancer Institute, London, United Kingdom)
and the luciferase gene was replaced by the hcTYMP sequence. All
vectors were produced and titrated as indicated elsewhere [19].
2.2. Animal procedures
All animal procedures were conducted in accordance with the
rules established by the Generalitat de Catalunya for the Care and
Use of Laboratory Animals and in compliance with the ARRIVE guide-
lines. The protocols were approved by the Ethics Committee for Ani-
mal Experimentation of the Vall d’Hebron Research Institute (Permit
Number: 1406).
A double knockout mouse for the genes Tymp and Upp1 previ-
ously described was used for this study [5]. AAV transduction effi-
ciency in mice is higher in males than females [27]. Thus, to avoid
sex-related variation in the results, only male animals were used in
this study.
For chronic oral nucleoside exposure (“exposed” mice), the ani-
mals’ drinking water was supplemented with 16.6 g/L of dThd and
dUrd (68.6 mM dThd and 72.3 mM dUrd) from weaning up to the
end of the study (22-month-old mice) [25]. Mice that were not
exposed to nucleoside administration are designated as “naïve” in
this study.
To study pharmacokinetics (PK) following acute nucleoside
administration (peak plasma concentration, area under the curve
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animals), a single dose was administered by oral gavage (10 mL/g
body weight of 16.6 g/L of dThd and dUrd aqueous solution, ie,
166 mg dThd + 166 mg dUrd/kg body weight). Blood samples were
collected immediately before nucleoside administration, and at
30 min, 1 h, 1.5 h, 2 h, 3 h, 5 h, and 8 h after administration. In the PK
study, mice were deprived of access to drinking water during the first
3 h after gavage.
To detect the influence of possible metabolic adaptation on PK in
chronically dThd/dUrd-treated mice (exposed group), acute dThd/
dUrd administration was studied under two different conditions:
mice without chronic oral dThd/dUrd treatment (naïve group), and
mice already receiving chronic dThd/dUrd treatment (exposed
group). In this latter case, dThd/dUrd was withdrawn from drinking
water 24 h before acute administration for the PK study.
Therapeutic vectors were administered to 8- to 11-week-old dKO
mice in a single intravenous injection (tail vein) of AAV-TBG at doses
(in vector genomes per kg, vg/kg) of 5 £ 1011, 1012, 2 £ 1012 and
1013, and AAV-AAT or AAV-HLP, both at doses of 2 £ 1012 and 1013.
Blood samples from live animals were collected from the saphe-
nous vein using EDTA capillaries (Microvette 200K3E, Sarstedt). At
the end of the study (age 22 months), mice were euthanized by cervi-
cal dislocation. Heart blood was immediately collected in EDTA-
treated tubes, and tissues (liver, brain, small intestine and gastrocne-
mius skeletal muscle) were excised and immediately frozen in liquid
nitrogen and stored at 80 °C. Before analysis, mouse tissues were
ground to a fine powder with a ceramic mortar and pestle without
defrosting in liquid nitrogen.
2.3. TP activity and nucleoside determination
Plasma dThd and dUrd concentrations were determined by HPLC-
UV, as previously described [22]. For TP activity, 100200 mg of pul-
verized tissue was homogenized with a plastic pestle in 800 mL of
lysis buffer. Homogenates were centrifuged at 20,000 x g for 30 min
at 4 °C, the supernatant protein concentration was measured [28],
and TP activity was determined as described elsewhere [29].
For dThd and dUrd quantification in tissue, 100200 mg of pul-
verized samples was homogenized with a plastic pestle in lysis buffer
with addition of 1 mM internal standard (isotope-labeled dThd:
13C1015N2-dThd) and TP activity inhibitors to prevent in vitro degra-
dation of nucleosides in homogenates: 100 mM of 5‑chloro-6-[1-(2-
iminopyrrolidinyl) methyl] uracil hydrochloride (strong TP-specific
inhibitor that does not inhibit uridine phosphorylase (UP), used in
liver homogenates containing high TP activity derived from AAV
transduction) or 100 mM 6-amino-5-bromouracil (TP and UP inhibi-
tor) and 100 mM tetrahydrouridine (cytidine deaminase inhibitor),
used in small intestine homogenates containing high TP and UP activ-
ity) [30]. Homogenates were centrifuged at 20,000 x g for 30 min at
4 °C, and protein concentration of the supernatant was measured
[28]. The supernatant was deproteinized by ultrafiltration (10 kDa
Amicon Ultra filters; Merck Millipore) at 14,000 x g for 30 min at 4 °
C. The ultrafiltrate was later used to measure nucleosides by LC-MS/
MS (liquid chromatography coupled to tandem mass spectrometry).
Components of the sample were resolved and detected as previously
described [23]. Serial dilutions of dThd and dUrd standards
(0.520mM) in lysis buffer and 1mM of internal standard were proc-
essed in parallel to generate calibration curves. dThd and dUrd con-
centrations in the samples were obtained from interpolation of the
peak areas relative to the internal standard in the calibration curve.
2.4. Vector copy number determination
DNA was isolated with phenol-chloroform from approximately
25 mg of frozen liver and dissolved in 10 mM TrisHCl, pH 8.0. Vector
genome copies per cell were quantified by qPCR on the 7900HT FastReal-Time PCR System (Applied Biosystems). hcTYMP DNA copy
number was quantified using the predesigned TaqMan MGB expres-
sion assay Hs00157317_m1 and referred to the murine single-copy
nuclear gene Ang1 using the predesigned TaqMan MGB gene expres-
sion assay Mm00833184_s1 as previously described [19]. Quantifica-
tions were based on a standard curve prepared with different
dilutions of plasmids containing hcTYMP DNA or a specific region of
the Ang1 gene.2.5. Motor performance
Motor coordination, balance and exercise tolerance were assessed
in 25-week-old mice by testing their time to fall in a rotarod appara-
tus (Ugo Basile Mouse Rota-Rod). The protocol included three train-
ing sessions of 2 min each at a constant 4-rpm speed prior to the test.
The test session was then started at a speed of 4 rpm for 15 s, fol-
lowed by a constant acceleration rate of 1 rpm/s for 45 s. Three test
sessions were carried out with each mouse and the three time-to-fall
values were recorded and averaged [25].2.6. Magnetic resonance imaging
Eighteen months-old mice were anesthetized with 4% (v/v) and
maintained with 1.5% (v/v) isoflurane in O2 at 1 L/min. Mice were
placed in prone position on a water-jacketed bed to maintain body
temperature (37 § 1 °C) and immobilized with bite-bar and ear-bars.
Stable respiration rate (5080 bpm) and rectal temperature were
monitored (SA Instruments, Stony Brook, NT).
1H-MRI studies were performed at the joint nuclear magnetic
resonance facility of the Universitat Autonoma de Barcelona and
Centro de Investigacion Biomedica en Red—Bioingeniería, Biomater-
iales y Nanomedicina (CIBER-BBN) (Cerdanyola del Valles, Catalo-
nia), Unit 25 of NANBIOSIS. Experiments were conducted on a 7T
Bruker BioSpec 70/30USR scanner (Bruker BioSpin GmbH, Ettlingen,
Germany) equipped with a 72-mm inner diameter linear volume
coil as a transmitter and a dedicated mouse brain surface coil as a
receiver. MRI data were acquired and processed on a Linux com-
puter using Paravision 5.1 software (Bruker BioSpin GmbH, Karls-
ruhe, Germany).
Low-resolution T2-weighted fast spin-echo images were initially
obtained in axial, sagittal, and coronal planes for use as reference
scout images. The following imaging parameters were applied: TE
(effective echo time) 36 ms; TR (repetition time) 2 s; ETL (echo train
length) 8; FOV (field of view) 1.92 £ 1.92 cm2 ; MTX (matrix size)
128 £ 128; ST (slice thickness) 1 mm; gap (gap between slices)
0.1 mm; NS (number of slices) 14 axial, 9 sagittal, 5 coronal; NA (num-
ber of averages) 1; and Expt (experiment time) 24 s per orientation.
T2 maps were acquired using a multi-spin multi-echo sequence.
T2-weighted images at 24 different TE values between 10 and
240 ms were acquired, with TR 3 s, FOV 1.92 £ 1.92 cm2, MTX
128£ 128, NS 8, ST 1 mm, and gap 0.1 mm, covering the whole brain
excluding the olfactory bulb and cerebellum (Supp. Figure 6a), with
Expt 4 min 48 s.
Voxel-wise T2 relaxation maps were calculated using Paravision
5.1 software. Regions of interest corresponding to the total brain and
excluding ventricular areas were manually outlined for each slice
and the mean T2 region values were calculated for each mouse.
For ventricular volume measurement, brain volume was manually
outlined in each slice. Within the selected brain region, ventricular
pixels were automatically pre-defined on T2 maps as pixels having
T2 values above 60 ms. The analysis was reviewed and non-ventricu-
lar regions were manually removed. The sum of ventricular pixels in
all slices was then multiplied by the voxel volume
(0.15 £ 0.15 £ 1 mm3) to provide the total ventricular volume for
each mouse.
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Liver and brain mitochondria were isolated and dNTPs were
extracted as previously described [4,19]. For dNTP quantification, dry
extracts were thawed and re-dissolved in 40 mL of 40 mM TrisHCl,
pH 7.4. Mitochondrial dNTP content was determined using the previ-
ously described polymerase-based method [31] with some modifica-
tions [19].
2.8. Mitochondrial DNA copy number analysis
Total DNA was isolated from approximately 25 mg of pulverized
frozen tissue with the QIAamp DNA Mini Kit (Qiagen) and dissolved
in 10 mM TrisHCl (pH 8). MtDNA copy number was quantified by
qPCR on the 7900HT Fast Real Time PCR System (Applied Biosystems)
using a probe targeted to the mitochondrial gene mt-Rnr2 (encoding
the 16S rRNA) and referred to the nuclear gene Ang1, following the
protocol detailed elsewhere [32].
2.9. Histochemical staining of small intestine
Longitudinal sections of jejune were analysed using the adapted
“Swiss roll” technique [33]. Jejune sections were fixed in 4% neutral
buffered formalin and embedded in paraffin for histological examina-
tion. Three-mm-thick slices were stained with Masson’s trichrome.
Images were taken using a FSX100 fluorescence microscope and the
software FSX-BSW (Olympus, Tokyo, Japan).
2.10. Statistical analysis
Statistical analyses were performed using the GraphPad Prism 6
program (GraphPad Software, Inc.). For multiple comparisons (multi-
ple comparisons with one reference group, and multiple compari-
sons of all groups compared with each other) the Kruskal-Wallis test
followed by the Dunn's multiple comparisons test was used. When
the only interest was to compare two groups defined by only one
variable (e.g., exposed group vs. non-exposed group), we used the
Mann-Whitney U test. In any case, tests used are always indicated in
the figure legends. For statistical purposes, undetectable values were
considered as zero. Nucleoside PK parameters, including peak
plasma concentration, AUC, and time to reach plasma WT concentra-
tion, were calculated from the graphical curves obtained by plotting
nucleoside plasma concentrations vs time, defined by connecting
adjacent measurements with straight lines, and taking as baseline
the mean plasma nucleoside concentration at time 0 h in naïve WT
mice.
2.11. Role of funding source
The disclosed funders had no role in study design, data collection
and analysis, interpretation, decision to publish, or preparation of the
manuscript.
3. Results
3.1. Pharmacokinetics of dThd and dUrd in the murine model
In agreement with previous reports [19-24], in the absence of oral
nucleoside administration (naïve mice), circulating dThd and dUrd
concentrations were around 3-fold higher in dKO mice than in WT
mice (Fig. 1a and Supplementary Fig. 1). A marked increase in plasma
dThd and dUrd concentrations above normal WT levels was observed
in the exposed groups. When the time of blood sample collection was
not considered, plasma dThd and dUrd concentrations showed wide
dispersion in the exposed groups (data not shown). This variability
was greatly reduced after changing the protocol and collecting allblood samples between 8 and 9 am (8- to 30-fold increase in exposed
WT mice, and 13- to 26-fold increase in exposed dKO mice) (Fig. 1a
and Supplementary Fig. 1). As mice were exposed to dThd and dUrd
in drinking water ad libitum, it was not possible to determine the
time of the last intake before blood collection. This may account for
the wide, randomly distributed variation in plasma concentrations;
that is, time differences between the last water intake and sample
collection.
Thus, we decided to explore a more controlled set of parameters,
by studying nucleoside PK in 35 to 40 week-old mice after a single
dThd/dUrd administration by oral gavage in naïve WT and dKO mice.
We also studied exposed WT and dKO mice to detect whether a pos-
sible metabolic adaptation in response to chronic dThd and dUrd
exposure influenced PK. After the single oral dose, plasma concentra-
tions rose above naïve dKO levels, reaching a peak value between 1
and 1.5 h after oral gavage (Fig. 1b and Supplementary Fig. 2a). There-
after, deoxyribonucleoside (dN) levels rapidly declined, even in dKO
mice, which lack the required catabolic enzymes, owing to urinary
excretion (data not shown). Eight hours after oral administration,
dThd and dUrd plasma levels remained above normal plasma levels
in all groups. Peak concentrations (Fig. 1c and Supplementary Fig. 2b)
and AUCs (Fig. 1d and Supplementary Fig. 2c) showed a clear ten-
dency to be higher in dKO mice than WT mice, in both the naïve and
exposed groups, respectively. We also found that AUC values were
higher in exposed dKO than in naïve dKO mice (Fig. 1d and Supple-
mentary Fig. 2c).
3.2. AAV-TYMP treatment limits nucleoside stress in chronically dThd/
dUrd -exposed dKO mice
Exposed dKO mice were treated with three different liver-tar-
geted AAV vectors carrying hcTYMP (AAV-TBG, AAV-AAT, or AAV-
HLP) at different doses. Plasma dThd and dUrd monitoring over 35
weeks showed the following: although AAV treatment failed to
reduce circulating levels of these nucleosides at most time points, the
frequency of randomly distributed samples in which nucleosides con-
centrations decreased to levels within the range of naïve dKO mice
(Supplementary Fig. 3) was higher than that of untreated exposed
dKO mice (Fig. 1a). As the last nucleoside intake (in drinking water)
before blood sample collection might have been interfering with
detection of the effect of AAV treatment on dN concentration, we
analyzed the effect of AAV treatment on PK parameters in gavage-
exposed dKO mice (Fig. 1b-e). Before gavage dosing, plasma dThd
and dUrd concentrations in all AAV-treated mice but one were in the
WT range or below (dThd, 1.93.5 mM; dUrd, 2.54.2 mM). It should
be noted that the group of exposed mice had been deprived of oral
dThd and dUrd in drinking water 24 h before PK assessment. AAV
treatment reduced peak dThd concentrations to well below the peak
concentrations observed in exposed dKO mice, regardless of the vec-
tor construct or dose used, although statistical significance was not
reached for the two AAV-TBG lowest doses (Fig. 1c). AAV treatment
led to even more pronounced reductions in the AUC (Fig. 1d). In con-
trast to what occurred in AAV-untreated mice, which did not reach
WT nucleoside levels after gavage nucleoside administration over 8 h
of monitoring (Fig. 1b), all AAV-treated exposed dKO mice reached
WT levels in less than 8 h (Fig. 1e). A dose-dependent effect in the
time reduction to reach WT dThd concentration was observed with
all vectors; a similar, but less marked dose-dependent effect was
observed on peak dThd concentration and dThd AUC. Comparison
between the different vectors showed that AAV-AAT had the most
pronounced effect on dThd PKs.
The greatest effect was achieved with AAV-AAT at 1013 vg/kg,
which reduced plasma dThd concentration to <3.5 mM in a
mean of 2.2 h (range 1.82.6 h) after oral gavage. Mice treated with
1013 vg/kg of AAV-AAT also showed the lowest mean dThd peak
concentration (13.8 mM, range 5.516.9) and the lowest mean
Fig. 1. Effect of AAV treatment on dThd pharmacokinetics. a) Plasma dThd concentration in WT and dKO mice exposed to dThd and dUrd supplementation in drinking water start-
ing from weaning (exposed group), or without exposure (naïve group). The monitored range encompasses 5 to 34 weeks of age. Each symbol and line represents a single mouse.
Gray dotted and shadowed areas indicate the concentration range in naïve dKO and WT groups, respectively. b) Plasma dThd concentrations before (0 h) and after a single adminis-
tration of dThd and dUrd by oral gavage (166 mg/kg each) in naïve and exposed WT mice, naïve and exposed dKO mice, and exposed dKO mice previously treated with different
doses of AAV-TBG, AAV-AAT and AAV-HLP vectors. Mice were 35 to 45 weeks old at the time of the experiment. Each point represents mean§range. White and gray areas between
dotted lines indicate the concentration range in naïve dKO and WT groups at time zero, respectively. c, d and e) PK results (mean+SD) obtained from experiments depicted at b.
Sample sizes in panels b to e are: naïve WT, n = 8; naïve dKO, n = 6; exposed WT, n = 5; exposed dKO, n = 7; TBG-treated mice with 5 £ 1011 vg/kg n = 2, 1012 vg/kg n = 4, 2 £ 1012
vg/kg n = 5, and 1013 vg/kg n = 5; AAT-treated mice with 2£ 1012 vg/kg n = 6 and 1013 vg/kg n = 5; HLP-treated mice with 2 £ 1012 vg/kg n = 6 and 1013 vg/kg n = 4. Asterisks indicate
statistically significant differences (*p<0.05, **p<0.01; panels c and d, Kruskal-Wallis test followed by the Dunn's multiple comparisons test, all groups compared with dKO exposed;
panel e, Kruskal-Wallis test followed by the Dunn's multiple comparisons test, all groups compared with each other). AUC, area under the curve.
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effects of AAV treatment on PK were observed for dUrd (Supple-
mentary Fig. 2).
Nucleoside-exposed mice were treated with dThd/dUrd in drink-
ing water from weaning until the end of the study (at 22 months
old). At this point, mice were killed and dThd and dUrd levels were
analyzed in plasma and liver (AAV target organ), as well as brain and
small intestine (two affected organs in MNGIE patients). Chronic oral
nucleoside exposure resulted in increased dThd median levels in all
tissues in WTmice (plasma 5-fold, liver 2-fold, brain 4-fold, and small
intestine 90-fold, as compared with median levels in naïve WT
group), and showed a higher increase in dKO mice (plasma 20-fold,
liver 10-fold, brain 7.5-fold, and small intestine 275-fold, as com-
pared with median levels in naïve WT group) (Fig. 2). In addition,
AAV-treatment reduced dThd and dUrd levels in nucleoside-exposed
mice at the end of the study in liver (reductions compared to exposed
dKO AAV-untreated, with levels comparable to those of WT naïve
mice) and in brain (reductions compared to untreated exposed dKOAAV, with levels comparable to those of exposed WT mice in all
groups and doses except the lowest AAV-TBG dose). In plasma,
reductions were especially prominent in mice treated with the AAV-
AAT vector (and reached statistical significance for the dose 2 £ 1012
vg/kg), whereas there was no effect in small intestine with any treat-
ment. The greatest reductions were obtained for the AAV-AAT vector
in plasma, liver, and brain. Similar results were observed for the dUrd
concentrations (Supplementary Fig. 4).
3.3. AAV-TYMP treatment induces increased TP activity in liver
Chronic nucleoside exposure induced increased TP activity in liver
tissue in WT mice (mean value 39 nmoles Thy/h/mg prot in naïve
WT, and 112 in exposed WT), and in dKO mice (mean value 1.2 in
naïve dKO, and 9.9 in exposed dKO) (Fig. 3a), but not in small intes-
tine, brain, or skeletal muscle (Supplementary Fig. 5). Treatment with
AAV vectors provided TP activity to liver of exposed mice in a dose-
dependent manner (Fig. 3b). AAV-AAT was the most effective vector
Fig. 2. Effect of AAV treatment on dThd levels in 22-month-old mice. Plasma, liver, brain, and small intestine dThd concentration in WT (n = 79) and dKO (n = 8) naïve mice, WT
(n = 4) and dKO (n = 10) exposed mice, and dKO exposed mice treated with different AAV doses (TBG-treated mice with 5 £ 1011 vg/kg n = 2, 1012 vg/kg n = 4, 2 £ 1012 vg/kg n = 6
and 1013 vg/kg n = 4; AAT-treated mice with 2 £ 1012 vg/kg n = 6 and 1013 vg/kg n = 4; HLP-treated mice with 2 £ 1012 vg/kg n = 6 and 1013 vg/kg n = 3). Horizontal lines indicate
the median concentration for each group. Asterisks indicate statistically significant differences (*p<0.05, **p<0.01; Kruskal-Wallis test followed by the Dunn's multiple comparisons
test, all groups compared with dKO exposed).
6 F. Vila-Julia et al. / EBioMedicine 62 (2020) 103133in providing TP activity to liver, in agreement with its nucleoside
reduction. At the highest dose (1013 vg/kg), liver TP activity mean val-
ues in exposed mice increased 40- to 75-fold compared to WT values:
2091§140 nmoles Thy/h/mg prot for AAV-TBG (mean§SD); 3031§
509 for AAV-AAT and 1535§456 for AAV-HLP (Fig. 3b).
Vector copy number (VCN) increased in liver in a dose-depen-
dent manner (Fig. 3c). In an attempt to compare the efficacy of
the promoters carried by the three vectors, we normalized TP
activity per VCN, and the results revealed that TP/VCN ratios were
not constant for each vector, but declined as VCN increased
(Fig. 3d). This apparent “saturation of efficacy” makes it difficult to
compare the efficacies of different promoters, but the fact that the
highest TP/VCN ratios were always observed with the AAV-AAT
vector for all different VCN values (Fig. 3d), suggests that AAT was
the most effective promoter among those tested. The TP vs VCN
distribution was adjusted to the nonlinear function:
Y = intercept + slope x log(X), where Y is TP activity and X is VCN.
Semilogarithmic transformation of the function showed that the
highest slope among the three vectors corresponded to AAV-AAT
(p<0.05, extra sum of squares F-test).
Although all the promoters used here are liver-specific, AAV treat-
ment provided TP activity to small intestine in exposed dKO mice, as
well as skeletal muscle treated with the highest vector doses, and
brain in a few individual mice. AAV-induced TP activities did not
reach levels above WT values in non-hepatic tissues except in a single
skeletal muscle sample (Supplementary Fig. 5).3.4. Histological analysis of small intestine and mtDNA copy number
Histological analysis of the small intestine (Masson’s trichrome
staining) did not reveal any detectable abnormalities induced by
nucleoside exposure in this tissue. Also, we could not find that nucle-
oside exposure induced mtDNA depletion in brain and small intes-
tine. (Supplementary figure 6).3.5. Effect of the AAV-TYMP treatment on neurological phenotype
Motor coordination, balance and exercise tolerance were deter-
mined using the rotarod performance test in 25 week-old mice
(Fig. 4). The performance in this test can be influenced by impaired
function of the skeletal muscles and/or the central nervous system.
Multiple comparison analysis of all groups represented in Fig. 4
(Kruskal-Wallis test, followed by the Dunn's multiple comparisons
test) did not detect statistical differences for any group, probably due
to the high number of groups. However, when we only analysed the
effect of nucleoside exposition, we observed that exposed dKO mice
had a reduced time to fall, as compared with WT naïve mice
(p = 0.006, Mann-Whitney U test) (Fig. 4). In AAV-treated mice,
rotarod performance varied widely, but in most AAV-treated mice
(69%; 27 out of 39) was within or above the naïve WT normal range
(1944 s), whereas only 33% (3 out of 9) of exposed dKO mice
showed a lengthier time to fall.
Fig. 3. TP activity in liver after AAV treatment. Liver TP activity in (a) WT (n = 8) and dKO (n = 8) naïve mice and in untreated WT (n = 4) and dKO (n = 10) exposed mice. (b) Liver TP
activity in untreated WT and dKO exposed mice and in dKO exposed mice treated with different AAVs doses (TBG-treated mice with 5 £ 1011 vg/kg n = 2, 1012 vg/kg n = 4, 2 £ 1012
vg/kg n = 6 and 1013 vg/kg n = 4; AAT-treated mice with 2 £ 1012 vg/kg n = 6 and 1013 vg/kg n = 4; HLP-treated mice with 2 £ 1012 vg/kg n = 6 and 1013 vg/kg n = 3). (c) Liver vector
copy number (VCN) in AAV-treated dKO exposed mice. TBG-treated mice with 5 £ 1011 vg/kg n = 1, 1012 vg/kg n = 4, 2 £ 1012 vg/kg n = 5 and 1013 vg/kg n = 4; AAT-treated mice
with 2 £ 1012 vg/kg n = 6 and 1013 vg/kg n = 4; HLP-treated mice with: 2 £ 1012 vg/kg n = 5 and 1013 vg/kg n = 3. Horizontal lines indicate the median for each group. (d) Non-linear
regression of liver TP activity (data from panel b) vs. liver VCN (data from panel c) in AAV-treated mice (Y = intercept + slope x log(X)). Note that the low VCN region is magnified to
facilitate observation of the differences between the three vectors. Asterisks indicate statistically significant differences (*p<0.05, **p<0.01; for panel a, Mann-Whitney U test; for
panel b, Kruskal-Wallis test followed by the Dunn's multiple comparisons test, all groups compared with each other, two different analyses for each dose).
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MRI [9], and chronic oral exposure to dThd and dUrd enhances leu-
koencephalopathy in the dKO murine model [25]. We performed
brain MRI studies in 84-week-old naïve and exposed WT and dKO
mice. Larger T2-weighted hyperintense areas (indicative of cerebro-
spinal fluid) were found in exposed dKO mice than in naïve dKO,
naïve WT, or exposed WT mice (Fig. 5a and Supplementary Fig. 7). In
contrast to what was reported in the former study of nucleoside
exposed dKO mice, we did not find leukoencephalopathy in our
experimental setting, probably because of different magnetic reso-
nance protocols [25]. Hyperintensity was mainly located in the third
and lateral ventricles, suggesting ventricular enlargement. The vol-
ume of the third and lateral ventricles was quantified using T2 maps,
and it was significantly greater in exposed dKO mice than in naïve
WT mice whereas it was unchanged in both naïve dKO and exposed
WT mice (Fig. 5b). AAV-AAT and AAV-HLP treatment prevented ven-
tricular enlargement in exposed dKO mice: most animals treated
with these vectors had normal ventricular volumes, with the excep-
tion of one mouse treated with 1013 vg/kg AAV-AAT that developed
hydrocephalus. In contrast, AAV-TBG failed to prevent ventricular
enlargement in most cases (Fig. 5b).
Ventricular volumes at 84 weeks of age significantly correlated
with brain dThd levels at the end of the study (94 weeks) in all groups
(Spearman r = 0.324, p = 0.014, n = 57, excluding 2 ventricular volumeextreme values; r = 0.358, p = 0.005, n = 59, including all values) and
with rotarod test performance (Spearman r =0.348, p = 0.0068,
n = 59, excluding two ventricular volume extreme values). Ventricu-
lar volumes did not significantly correlate with plasma or liver dThd
levels.
3.6. AAV-TYMP treatment normalized the mitochondrial dNTP balance
In MNGIE, nucleoside overload leads to an unbalanced dNTP mito-
chondrial pool, resulting in mtDNA instability [4]. We quantified
dNTP levels in mitochondrial extracts from liver and brain in 22-
month-old mice (Fig 6). dTTP content was significantly increased in
brain mitochondria of exposed dKO mice. The same trend was
observed in liver mitochondria, but statistical significance was not
reached, probably owing to the wide dispersion of the values (liver
dTTP range: 5.354.7 pmoles/mg protein). The dTTP expansion in
liver was largely prevented in exposed dKO mice treated with AAVs,
as most values of AAV treated mice returned to dTTP values with the
naïve WT range, although only the group treated with AAV-TBG at
1013 vg/kg reached statistical significance (Fig. 6a). AAV treatment
also limited dTTP expansion in brain, but the effect was only partial
as dNTP in AAV-treated animals did not reach WT levels (and reached
statistical significance only in the group treated with AAV-AAT at
2 £ 1012 vg/kg) (Fig. 6b). The observations regarding mitochondrial
Fig. 4. Motor function. Motor function assessed by rotarod test in 25-week-oldWT and
dKO naïve and exposed mice, and dKO exposed mice treated with different AAVs
doses. Horizontal lines show median time to fall in each group. Gray areas indicate the
range of values in the naïve WT group. No statistical differences found, Kruskal-Wallis
test followed by the Dunn's multiple comparisons test, all groups compared with dKO
exposed).
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exposed dKO showed dCTP depletion as compared with WT levels,
which was largely prevented by AAV treatment, reaching statistical
significance for all AAV-AAT treated groups, and for the group treated
with AAV- HLP at 2 £ 1012 vg/kg (Fig. 6c). No statistical differences
were detected in mitochondrial dCTP levels in brain (Fig. 6d). As to
the purine deoxynucleotides, mitochondrial dGTP levels were
expanded in liver (an increase that was not prevented by AAV treat-
ment), while dATP showed a tendency to be depleted in the same
organ (statistically non-significant), but the effect was prevented in
most AAV treated groups. In contrast, mitochondrial dATP and dGTP
levels were barely affected or not affected at all in brain (Supplemen-
tary Fig. 8).
4. Discussion
Over the last few years, gene therapy has been proposed to reduce
the relevant risks associated with the currently available options to
treat MNGIE (allogeneic stem cell transplantation and orthotopic
liver transplantation) [11-13,15-18,34]. Since the first proof-of-
concept preclinical studies demonstrating the feasibility of using len-
tiviral[22] and AAV vectors [23], several studies have shown that
these strategies provide maintained effectiveness at long term in the
preclinical model [19-21,24]. The main endpoint used to draw con-
clusions was the ability of the vectors to achieve genetic correction in
target cells of the murine dKO model, thereby providing TP activity
and normalization of systemic dThd and dUrd levels.
However, the dKO mouse is a limited model due to the absence of
a clinically relevant phenotype, which consists of a lack of TP activity
(except for some residual activity in tissues expressing Upp2), moder-
ate dThd and dUrd systemic accumulation, and a modest mitochon-
drial dNTP imbalance. Any additional traits beyond the biochemical
consequences of the absence of TP have only been glimpsed in very
old animals and, even so, as elusive and barely detectable signs [5].
The model can be enhanced by providing the animals with dThd and
dUrd in drinking water, which exacerbates the phenotype and high-
lights the importance of dThd and dUrd overload in the pathophysiol-
ogy of MNGIE [25]. This enhanced model does not recapitulate the
main clinical features of the disease (which manifest mainly as severe
gastrointestinal dysmotility, myopathy, peripheral neuropathy and
brain diffuse leukoencephalopathy). Specifically, the lack of gastroin-
testinal phenotype is an important limitation of this animal model,because gastrointestinal dysmotility is the most debilitating symp-
tom in MNGIE patients [9]. However, it does show some new func-
tional and radiological alterations (neuromotor dysfunction and
ventricular alterations in brain) that are absent or much less promi-
nent in the non-nucleoside exposed murine model. We used this
enhanced preclinical model to expand on our previous studies dem-
onstrating the feasibility and efficacy of AAV-based liver-targeted
gene therapy for MNGIE [19,21,23].
Systemic dThd and dUrd levels in naïve dKO mice were 2- to 4-
fold higher than levels in naïve WT mice, as was originally reported
[5] and consistently observed here, which contrasts with the much
more pronounced accumulations (more than 50-fold) observed in
MNGIE patients [35,36]. In agreement with the study where the
stressed model was established [25], we found that oral administra-
tion of dThd and dUrd to dKO mice exacerbates systemic accumula-
tion of both dNs. Furthermore, the highest dThd and dUrd
accumulations were seen in small intestine, likely because of the
presence of ingested dNs, before or during intestinal absorption. In
contrast, we found detectable dThd and dUrd levels in all tissues ana-
lyzed from naïve WT mice, and exposed dKO mice had dN levels only
20-fold above WT plasma values, and 10-fold above liver and brain
WT values. These discrepancies likely result from the use of TP activ-
ity inhibitors during sample processing for dN determination, which
prevented in vitro dN degradation in WT samples and reduced the
differences between naïve WT and exposed dKO concentrations. As
was expected, the excess of dThd and dUrd resulted in enhanced
mitochondrial dNTP imbalances (dTTP increase and dCTP depletion)
in the two tissues analyzed (liver and brain).
We found an unreported effect of dN exposure on mice: an
increase in TP activity in liver, but not in skeletal muscle, small intes-
tine, or brain. A similar effect (TYMP upregulation) has been reported
in cultured human cells in response to dThd and nucleoside analogues
[37]. Exposure to dN doubled liver TP activity in WT mice and, inter-
estingly, also increased activity in dKO animals. Upregulation of Tymp
or other genes encoding enzymes with TP activity (such as Upp1 and
Upp2) may account for this increase in WT mice. Additionally, dThd
excess could be inhibiting the ubiquitin-mediated TP degradation as it
has been recently reported in human differentiating reticulocyte cell
cultures [38]. In contrast, Tymp and Upp1 genes are molecularly inacti-
vated in the dKO model [5,39]; therefore, dN-induced TP activity in
these animals should be mediated by upregulation of another
enzyme, likely UP2 (encoded by Upp2). In fact, naïve dKO mice have
some detectable TP activity in liver that must be due to UP2.
All MNGIE patients present diffuse leukoencephalopathy on brain
MRI, but this abnormality is barely detectable in naïve dKO mice, and
is only seen when they are very old [5]. The first study of the nucleo-
side-exposed dKO model demonstrated that chronic exposure to
dThd and dUrd led to increased brain MRI FLAIR intensity signal
around the third and lateral ventricles [25]. In our study, we failed to
detect MRI differences between naïve dKO and naïve WT mice, show-
ing how elusive this feature is in the unexposed mouse model. None-
theless, and in agreement with the previous report [25], dKO mice
(but not WT mice) did develop the MRI phenotype under dN expo-
sure, although we found enlarged ventricle volumes rather than the
diffuse parenchymal leukoencephalopathy that is typically observed
in MNGIE patients. Combined analysis of T2 maps and high-resolu-
tion T2-weighted images revealed that the periventricular signal
hyperintensity corresponds to enlarged ventricular volume, with no
fluid transfer to the surrounding white matter, in contrast to what is
observed in other hydrocephalic models with severe ventricular
enlargement [40]. Exposure to dNs also succeeded in the develop-
ment of a motor function phenotype. At 25 weeks of age, exposed
dKO mice showed a shorter time to fall in the rotarod test, which is
indicative of motor coordination impairment in this model, in agree-
ment with previous findings [25]. Furthermore, rotarod time to fall at
25 weeks of age inversely correlated with MRI ventricular volume
Fig. 5. Brain MRI analysis. (a) Coronal T2-weighted and T2 map images of 1-mm sections (region corresponding to slice 6 in Supp Figure S7) showing ventricular enlargement in
dKO exposed mice (red arrows). (b) Ventricular volume in 80 to 84-weeks old WT (n = 9) and dKO (n = 5) naïve mice, non-treated WT (n = 5) and dKO (n = 12) exposed mice, and
dKO exposed mice treated with different AAVs doses (TBG-treated mice with: 5 £ 1011 vg/kg n = 2, 1012 vg/kg n = 3, 2 £ 1012 vg/kg n = 5 and 1013 vg/kg n = 5; AAT-treated mice
with: 2 £ 1012 vg/kg n = 6 and 1013 vg/kg n = 4; HLP-treated mice with: 2 £ 1012 vg/kg n = 6 and 1013 vg/kg n = 3). Ventricular volume was quantified in T2 maps as the sum of the
ventricular volumes calculated in all sections analyzed in Supp Figure S6 (see materials and methods for calculations). Gray areas indicate the range of values in the naïve WT group.
Asterisks indicate statistically significant differences (*p<0.05; Kruskal-Wallis test followed by the Dunn's multiple comparisons test, all groups compared with dKO exposed). Ven-
tricular volume values above the mean plus 3 SD of all data were considered outliers and excluded from the analysis. Two outliers were identified in dKO exposed AVV-treated with
TBG 1012 vg/kg, and TBG 2 £ 1012 vg/kg, one in each group.
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associating hydrocephalus with motor function defects [41].
As was discussed above, most effects of dN exposure seen in our
study are consistent with previously reported findings [25], but we
failed to replicate some other important features. After careful histo-
logical analysis (Masson’s trichrome staining), we found no abnor-
malities in small intestine of exposed mice, and no mtDNA depletion
was detected in brain or in small intestine.
In previous preclinical studies, we used the TBG promoter in AAV
gene therapy for MNGIE and proved that it is effective for drivinghcTYMP expression [21,23]. The need to optimize therapeutic gene
expression and minimize the vector dose to transfer therapy to
MNGIE patients prompted us to explore new vector constructs [19].
The ApoE-AAT enhancer-promoter cassette has been used in several
AAV-based preclinical and clinical studies [42-45]. The self-comple-
mentary genome configuration resulted in faster and stronger thera-
peutic gene expression in these studies, and it has also been
successfully used in patients [46-48]. We found that use of the AAV-
AAT vector to carry hcTYMP in the dKO model resulted in greater
efficacy as compared to other hepatic promoters or a self-
Fig. 6. Mitochondrial dNTPs. Mitochondrial thymidine triphosphate (dTTP) and deoxycytidine triphosphate (dCTP) content in liver (a and c) and brain (b and d) of WT (n = 9) and
dKO (n = 8) naïve mice, non-treated WT (n = 4) and dKO (n = 10) exposed mice and dKO exposed mice treated with different AAVs doses (TBG-treated mice with: 5 £ 1011 vg/kg
n = 2, 1012 vg/kg n = 4, 2 £ 1012 vg/kg n = 6 and 1013 vg/kg n = 4; AAT-treated mice with: 2 £ 1012 vg/kg n = 6 and 1013 vg/kg n = 4; HLP-treated mice with: 2 £ 1012 vg/kg n = 6 and
1013 vg/kg n = 3). Horizontal lines indicate the median for each group. Gray areas indicate the range of values in the naïve WT group. Asterisks indicate statistically significant differ-
ences (*p<0.05, **p<0.01; Kruskal-Wallis test followed by the Dunn's multiple comparisons test, all groups compared with dKO exposed).
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enhanced nucleoside-exposed animal model to expand the study, we
found that AAV-AAT provides an effect beyond the previously
reported biochemical normalization. AAV-AAT performed better than
other liver-targeted vectors in restoring biochemical homeostasis
(nucleoside reduction, liver TP activity, dNTP normalization), and it
also improved the brain MRI abnormalities manifested in the
exposed mouse model.
Our attempts to determine the effect of different vectors on dN
homeostasis revealed an unexpected limitation of the model. As mice
received dNs in their drinking water ad libitum, the variability in dN
levels seen over the day was likely determined by the last time the
mouse drank water. To circumvent this confounding factor, we
decided to determine PK parameters (peak concentration, AUC, and
time to reachWT values) after a single gavage administration, instead
of single dN values in one blood sample, as more reliable biochemical
endpoints to study the effect of the vectors on dN homeostasis in the
model. A vector dose-response was observed in most cases, and com-
parison between the three vectors showed that AAV-AAT was the
most efficient to reduce plasma dN levels, which is consistent with
their better comparative ability to provide TP activity to liver. As was
expected, all vectors led to substantial dose-dependent TP activity in
liver, and the analysis of TP activity/vector copy number ratios indi-
cated that the AAT promoter was the most efficient. All these obser-
vations confirm and reinforce our previous results on the efficacy of
different vectors [19].Previously, we observed that treatment with AAV-TBG, AAV-HLP
and AAV-AAT results in sporadic cases of increased TP activity in
non-hepatic tissues [19], and this was confirmed here in an indepen-
dent set of experiments. In our previous report, we found that this
“illegitimate activity” seems not to be caused by ectopic expression,
as transgene DNA or mRNA could not be consistently found in sam-
ples with TP activity. Hence, this activity might respond to exosomal
export from liver [49]. In any case, this extra-hepatic effect was irrel-
evant in quantitative terms in both the previous and the current
study.
dNTP imbalances were ameliorated in liver as a consequence of
the systemic dN reduction. The effect in brain, however, was only
partial. The fact that liver, but not brain, is the target of the vectors
tested here may account for the modest effect in brain. In addition,
the anatomic complexity of the brain, constituted by many cell types
distributed among different functional areas, may mask local effects,
as our method for mitochondrial dNTP determination is performed
on total brain mitochondria. Interestingly, dCTP depletion could not
be detected in brain mitochondria, which correlates with the absence
of mtDNA depletion in this organ, in agreement with previous experi-
mental data showing that the cause of mtDNA depletion in MNGIE is
limited availability of dCTP [4].
Of note, this is the first time that AAV-mediated gene therapy has
shown efficacy on disease-related features in MNGIE beyond normal-
ization of the biochemical imbalances. Nucleoside-exposed mice
treated with AAV-HLP and AAV-AAT vectors recovered normal
F. Vila-Julia et al. / EBioMedicine 62 (2020) 103133 11ventricular volumes on MRI, while this effect was only partial (in
some mice) and not statistically significant with the AAV-TBG vector.
When all mice were taken as a whole, ventricular volumes signifi-
cantly correlated with dThd levels in brain, reinforcing the notion
that normalization of the biochemical imbalances is directly related
with improvements in this neurological trait. However, the results
did not allow us to draw clear conclusions on the effect of therapy on
motor function, as assessed with the rotarod test. Time to fall in the
rotarod test was shorter in nucleoside-exposed dKO mice, which can
be due to alterations in the central nervous system and/or the skele-
tal muscle. This reduction seemed to be prevented in most groups of
AAV-treated mice. However, if this observation suggests a positive
effect of the treatment, it is uncertain why was it not observed at the
highest vector doses. The reasons for this apparent paradox remain
to be explored.
The results of this study show that the AAV-AAT vector performed
the best among those tested, efficiently providing TP activity to the
liver and restoring dN and dNTP homeostasis. In addition, functional
improvements on the phenotype beyond normalization of biochemi-
cal markers were proven for AAV-mediated MNGIE gene therapy in
the nucleoside-exposed dKO mouse model. AAV transduction rates
are lower in humans than in mice [50,51]; therefore, using more
potent promoters, within a reasonable range of potency, will be nec-
essary to make AAV treatment possible in humans at feasible vector
doses. This will have an impact on both biosafety and the cost of
treatment, and contribute to facilitating implementation of this ther-
apy in patients, which constitutes a significant advance towards the
treatment of this devastating disorder with a much less invasive ther-
apy than those currently available.
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